Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 200Lymphoma 199Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Leukemia 89Hodgkin Disease 89Lymphoma, Mantle-Cell 80Lymphoma, B-Cell, Marginal Zone 66Burkitt Lymphoma 65Leukemia, Myeloid, Acute 55Multiple Myeloma 52Lymphoma, Large-Cell, Immunoblastic 48Recurrence 44Neoplasms 38Myelodysplastic Syndromes 38Lymphoma, T-Cell, Cutaneous 36Mycosis Fungoides 30Lymphoma, Large-Cell, Anaplastic 30Waldenstrom Macroglobulinemia 28Leukemia, Myeloid, Chronic-Phase 28Myeloproliferative Disorders 27Lymphoma, B-Cell 27Leukemia, Myeloid, Accelerated Phase 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 26Sezary Syndrome 25Leukemia, Biphenotypic, Acute 25Blast Crisis 24Primary Myelofibrosis 22

Interventions

zanubrutinib 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × B-cell Malignancies × Lymphoid × Clear all
NCT04170283 2025-10-21

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

BeOne Medicines

Phase 3 Active not recruiting
955 enrolled
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡